IPX066: Phase III data

Top-line data from the double-blind, crossover, international Phase III ASCEND-PD trial in 84 evaluable patients with advanced PD showed that IPX066 met the primary endpoint of significantly reducing the percentage of "off" time

Read the full 333 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE